Nguyen Tan

发表

CHIR-265, a novel inhibitor that targets B-Raf and VEGFR, shows efficacy in a broad range of preclinical models

Fernando Salangsang, E. Venetsanakos, D. Stuart, 2006 .

Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma

E. Anaissie, H. Kantarjian, G. Garcia-Manero, 2004, Clinical Cancer Research.

Phase II Study of SU 5416 , a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor , in Patients with Refractory Multiple Myeloma

E. Anaissie, H. Kantarjian, G. Garcia-Manero, 2004 .

Voreloxin Is an Anticancer Quinolone Derivative that Intercalates DNA and Poisons Topoisomerase II

Michelle R. Arkin, Andrew Conroy, Robert S. McDowell, 2010, PloS one.

Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models

J. Settleman, Leslie B. Lee, W. Fairbrother, 2013, Molecular Cancer Therapeutics.

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

M. Amiot, F. Peale, Leslie B. Lee, 2016, Molecular Cancer Therapeutics.

Expression of Bcl-2 Pro-Survival Family Proteins Predicts Pharmacological Responses to ABT-199, a Novel and Selective Bcl-2 Antagonist, in Multiple Myeloma Models

F. Peale, Leslie B. Lee, W. Fairbrother, 2012 .

Navitoclax Enhances the Efficacy of Taxanes in Non–Small Cell Lung Cancer Models

J. Zha, W. Fairbrother, L. Berry, 2011, Clinical Cancer Research.

Navitoclax (ABT-263) Reduces Bcl-xL–Mediated Chemoresistance in Ovarian Cancer Models

F. Peale, J. Zha, W. Fairbrother, 2012, Molecular Cancer Therapeutics.

Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor

J. Cherrington, G. McArthur, K. West, 2004, Oncogene.

Chemical Therapeutics Bcl-2 / Bcl-xL Inhibition Increases the Ef fi cacy of MEK InhibitionAlone and inCombinationwith PI 3 Kinase Inhibition in Lung and Pancreatic Tumor Models

J. Settleman, Leslie B. Lee, W. Fairbrother, 2013 .

Characterization of a novel Raf kinase inhibitor that causes target dependent tumor regression in human melanoma xenografts expressing mutant B-Raf

Wei Zhang, Edward G. Lorenzana, Fernando Salangsang, 2006 .

Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma.

S. Panowski, R. Galetto, J. Chaparro-Riggers, 2022, Cancer research.

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

M. Amiot, F. Peale, Leslie B. Lee, 2016, Molecular Cancer Therapeutics.

Navitoclax (ABT-263) Reduces Bcl-xL–Mediated Chemoresistance in Ovarian Cancer Models

F. Peale, J. Zha, W. Fairbrother, 2012, Molecular Cancer Therapeutics.